As of Friday close, ADMA Biologics Inc.’s (NASDAQ:ADMA) stock was down -$0.03, moving down -0.96 percent to $3.10. The average number of shares traded per day over the past five days has been 4,138,040 shares. 2 times new highs have been achieved over the past 5 days, with a $0.01 gain in that time frame. In the last twenty days, the average volume was 2,562,335, while in the previous 50 days, it was 2,497,982.
Since last month, ADMA stock retreated -13.41%. Shares of the company fell to $3.01 on 03/13/23, the lowest level in the past month. A 52-week high of $3.98 was reached on 01/03/23 after having rallying from a 52-week low of $1.43. Since the beginning of this year, ADMA’s stock price has dropped by -20.10% or -$0.78, and marked a new high 1 time. However, the stock has declined by -22.11% since its 52-week high.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
ADMA stock investors should be aware that ADMA Biologics Inc. (ADMA) stock had its last reported insider trading activity 99 days ago on Dec 09. Grossman Adam S, the President and CEO of the company, purchased of 14,983 shares for $2.86 on Dec 09. It resulted in a $42,851 investment by the insider. Grossman Adam S added 14,982 shares at an average price of $2.86 on Dec 09. The insider now owns 1,143,426 shares following the transaction. On Dec 09, EVP, CFO LENZ BRIAN bought 6,993 shares at $2.86 apiece. The transaction was valued at $20,000.
The stock’s beta is 0.93. Besides these, the trailing price-to-sales (P/S) ratio of 5.49, the price-to-book (PB) ratio of 6.08.
In the three months ended September 29, ADMA Biologics Inc.’s quick ratio stood at 1.40, while its current ratio was 5.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 1.41, and the total debt-to-equity ratio was 1.41. On the profitability front, the trailing twelve-month gross margin is 18.90% percent. In the year ended September 29, operating margins totaled -40.70%. Based on annual data, ADMA earned $1.17 million in gross profit and brought in $80.94 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -24.70%. Return on equity (ROE) for the past 12 months was -58.30%.
In ADMA Biologics Inc.’s quarter-end financial report for September 29, it reported total debt of $141.37 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ADMA’s revenue rose 49.67% to $33.91 million during the quarter, while net income inched up to $41.09 million. While analysts expected ADMA Biologics Inc. to report -$0.08 quarterly earnings, the actual figure was -$0.08 per share. During the quarter, the company generated -$6.51 million in EBITDA. The liabilities of ADMA Biologics Inc. were 200.17 million at the end of its most recent quarter ended September 29, and its total debt was $152.72 million. The value of shareholders’ equity is $196.78 million.
This quick technical analysis looks at ADMA Biologics Inc.’s (ADMA) price momentum. With a historical volatility rate of 42.10%, the RSI 9-day stood at 30.50% on 17 March.
With respect to its five-day moving average, the current ADMA Biologics Inc. price is up by +0.32% percent or $0.01. At present, ADMA shares trade -10.66% below its 20-day simple moving average and +15.67% percent above its 100-day simple moving average. However, the stock is currently trading approximately -15.07% below its SMA50 and +51.22% above its SMA200.
Stochastic coefficient K was 16.67% and Stochastic coefficient D was 21.55%, while ATR was 0.15. Given the Stochastic reading of 13.64% for the 14-day period, the RSI (14) reading has been calculated as 34.75%. As of today, the MACD Oscillator reading stands at -0.10, while the 14-day reading stands at -0.18.
Mizuho launched its rating on ADMA Biologics Inc. (NASDAQ: ADMA) to a Buy in a note to investors on October 13, 2022. ADMA Biologics Inc. (ADMA) has been rated Buy by analysts. According to 0 brokerage firms, ADMA is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ADMA Biologics Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $5.00, the current consensus forecast for the stock is $4.50 – $6.00. Based on these forecasts, analysts predict ADMA Biologics Inc. (ADMA) will achieve an average price target of $5.13.